Investigating NMJ Defects in SMA Following Central and Peripheral SMN Restoration

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Spinal Muscular Atrophy
Interventions
DRUG

Risdiplam

"Risdiplam is administered orally once daily and the recommended dosage is determined by age and body weight (see Table 1) \[as outlined in the US Prescribing Information for EVRYSDI™(risdiplam)\].~Table 1 Adult and Pediatric Dosing Regimen by Age and Body Weight: US Prescribing Information~Age and Body Weight (Recommended Daily Dosage): 2 months to less than 2 years of age (0.2 mg/kg); 2 years of age and older weighing less than 20 kg (0.25 mg/kg); 2 years of age and older weighing 20 kg or more (5 mg)"

Trial Locations (1)

43210

RECRUITING

The Ohio State University Wexner Medical Center, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Bakri Elsheikh

OTHER

NCT05219487 - Investigating NMJ Defects in SMA Following Central and Peripheral SMN Restoration | Biotech Hunter | Biotech Hunter